Emergent BioSolutions is well known for owning the rights to the pioneering technology behind the Narcan nasal spray. Naloxone has been around for years as an injectable for opioid overdoses which required expertise to administer. Narcan spray eliminated the expertise requirement.
Recently, EBS entered into several large contracts with giant pharma and will serve as manufacturers of leading COVID-19 vaccine candidates. They are working with Department of Defense; Department of Health and Human Services; Johnson & Johnson; and AstraZeneca.
The deal with JNJ starts in 2021 and lasts 5 years.
As more and more vaccines pass trials and get approved, biotech companies will need a manufacturer to sign with and I believe that EBS will be the go-to because of their size and ability to scale.
Currently waiting for a buy signal.
Komentar
⋅
Buy signal is in.
Komentar
⋅
Did some tweaks to the script. The pattern that appears repeat is: the dominant trend will reverse once price enters the colored areas.
Additionally, the holding period for this stock range from 2 weeks to 1 month.
i think, now its the time to go long as this really good discount, long term should be fine
GaryBeta
⋅
Caught likely my final buy at $96 today, fully long invested. Short term target $122, long term $150 with more approved vaccines buying services. Down now due to the J+J vaccine halt and prior AstraZeneca halt but best in the business.
GaryBeta
⋅
Own and looking to buy more. Buy signal will be at the $97.03 gap, been waiting a while!